Literature DB >> 6467797

Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects.

N M Woolhouse, K K Adjepon-Yamoah, B Mellström, A Hedman, L Bertilsson, F Sjöqvist.   

Abstract

Eleven Ghanaian and 12 Swedish subjects phenotyped with a debrisoquine (D) hydroxylation test were given a single oral dose of nortriptyline (NT). Much the same percentage of the given NT dose was excreted as 10-hydroxy-NT (10-OH-NT) by Ghanaians (43.1%) and Swedes (49.2%). There was a close correlation between plasma clearance of NT by 10-hydroxylation and the D metabolic ratio (D/4-OH-D in urine) in the Ghanaians (rs = -0.95; P less than 0.01) and Swedes (rs = -0.84; P less than 0.01). The E-isomer of 10-OH-NT is the major isomer in both Ghanaians (76% to 92% of total 10-OH-NT) and Swedes (78% to 95%). It is suggested that the E-10-hydroxylation of NT and the 4-hydroxylation of D are similarly coregulated in Ghanaians and Swedes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6467797     DOI: 10.1038/clpt.1984.190

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  Population pharmacokinetics and pharmacodynamics: potential use for gathering dose-concentration-response.

Authors:  M Jerling
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

2.  Inter-subject and ethnic differences in paracetamol metabolism.

Authors:  J A Critchley; G R Nimmo; C A Gregson; N M Woolhouse; L F Prescott
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

Review 3.  Clinical trials and transethnic pharmacology.

Authors:  M E Kitler
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 4.  Pharmacogenetic phenotyping and genotyping. Present status and future potential.

Authors:  F J Gonzalez; J R Idle
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

5.  3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.

Authors:  Yueying Zhen; Ondrej Slanar; Kristopher W Krausz; Chi Chen; Josef Slavík; Kerry L McPhail; T Mark Zabriskie; Frantisek Perlík; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Dispos       Date:  2006-06-16       Impact factor: 3.922

6.  Sparteine oxidation polymorphism in Greenlanders living in Denmark.

Authors:  K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

7.  Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.

Authors:  K Brøsen; R Klysner; L F Gram; S V Otton; P Bech; L Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method.

Authors:  M Jerling; Y Merlé; F Mentré; A Mallet
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

9.  Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.

Authors:  K K Nielsen; K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio.

Authors:  C Nordin; B Siwers; J Benitez; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.